论文信息 - POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients - 字舞流文

POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients

C. Katlama | A. Lazzarin | A. Pozniak | B. Grinsztejn | S. Spinosa‐Guzman | N. Bellos | T. Casteele | S. Meyer